Day One Biopharmaceuticals, Inc. DAWN NASDAQ

Day One Biopharmaceuticals, Inc. (DAWN) generated $-103.76M in operating cash flow for fiscal year 2025. After capital expenditures of $320K, free cash flow was $-104.08M.

Free cash flow margin was -65.8% of revenue. Cash conversion ratio was 0.97x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (55/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.97x suggests some earnings are non-cash items

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.